In clinical trials4,5Evidence: Smaller human trialsMetabolic and weight

Eloralintide4

Key takeaway

Eloralintide is a synthetic peptide that activates the amylin receptor, recorded in FDA’s substance registry and in development for weight management.4,5 In a randomized, placebo-controlled Phase 2 trial of 263 adults with obesity or overweight, average weight change after 48 weeks ranged from 9% to 20% lower across eloralintide groups, compared with 0.4% lower on placebo.5 No FDA approval is reported in the sources reviewed here, and eloralintide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.4,8

Eloralintide at a glance

What it isA synthetic, selective amylin receptor agonist peptide, also recorded as AMY-1176 in FDA’s substance registry.4,5
FDA statusNot FDA-approved. None of the sources reviewed here reports an approval of eloralintide.4,5
Human evidenceA 48-week randomized, double-blind, placebo-controlled Phase 2 trial in 263 adults with obesity or overweight, published in 2025.5
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is eloralintide?

Eloralintide is a synthetic peptide recorded in FDA’s substance registry as eloralintide and AMY-1176.4

The 2025 trial report describes it as a novel, selective amylin receptor agonist in development for weight management; the trial was funded by Eli Lilly.5

How is eloralintide thought to work?

It is designed to act selectively on the receptor for the hormone amylin. The trial authors place it among amylin-based therapies emerging as obesity medicines.5

What do human studies show?

The Phase 2 trial randomized 263 adults with obesity, or with overweight and a weight-related condition, and without type 2 diabetes, to one of several eloralintide groups or placebo for 48 weeks.5

Average body weight fell by 9% to 20% across eloralintide groups, compared with 0.4% on placebo. Nausea and fatigue were the most common adverse events and were more frequent in some eloralintide groups than with placebo.5

ClinicalTrials.gov lists several Phase 3 trials of eloralintide as recruiting in 2026 registry records, including trials in obesity or overweight (NCT07321886), in osteoarthritis with overweight or obesity (NCT07353931) and in obstructive sleep apnea with obesity (NCT07369011).1,2,3

What the evidence base contains

  • Controlled human trial A 48-week, double-blind, randomized, placebo-controlled Phase 2 trial (NCT06230523) in 263 adults with obesity or overweight and no type 2 diabetes, at 46 U.S. sites (2025).5

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is eloralintide FDA-approved?

None of the sources reviewed here reports an approval of eloralintide by FDA.4,5

Eloralintide remains in clinical trials: Phase 3 registrations such as NCT07321886 are listed as recruiting in their 2026 records.1

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list eloralintide.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Eloralintide is not among them.7,8

Timeline

  1. The 48-week Phase 2 trial of eloralintide in 263 adults is published.5

What is still unknown?

Whether the weight loss seen in a 263-person Phase 2 trial holds in larger, longer trials, and how it compares with other obesity medicines, which the trial did not test.5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Eloralintide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Eloralintide are a bounded selection, not every registration or paper about Eloralintide. For the years before Eloralintide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Eloralintide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Eloralintide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 2 trial of 263 adults, weight fell by 9% to 20% across eloralintide groups over 48 weeks. Eloralintide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Eloralintide?

In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 2 trial of 263 adults, weight fell by 9% to 20% across eloralintide groups over 48 weeks. Eloralintide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
2
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 13, 2026

ClinicalTrials.gov record NCT07935304↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Eloralintide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

20Selected dated records
25Connected citations
2Populated source years2025–2026
2/4Record lanes present

Registered human studies

Trial composition

19 of 19 selected trial records include at least one phase value; 19 of 19 include a status value in the retained structured contract.

PhasesPhase 1 10Phase 3 6Phase 2 3
Status at observationRecruiting 10Active, not recruiting 3Completed 3Not yet recruiting 3

PubMed bibliography

Publication composition

1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesClinical Trial, Phase I 1Journal Article 1Multicenter Study 1Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
20

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 20 dated records

Research hub

Explore the Eloralintide evidence record

Open all 20 records →
20Dated records
2Evidence types
20Cited public sources
2Source years

Change ledger

Recently changed for Eloralintide

Open all 20 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT06230523

PeptideScanner retained ClinicalTrials.gov record NCT06230523 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was eloralintide.

PeptideScanner change date
November 16, 2026
Cited source date
June 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06916065

PeptideScanner retained ClinicalTrials.gov record NCT06916065 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was eloralintide.

PeptideScanner change date
November 16, 2026
Cited source date
January 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06916091

PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide.

PeptideScanner change date
November 16, 2026
Cited source date
November 19, 2025
Evidence lane
Clinical trials

Official-source collections

Source records for Eloralintide

Open the full research atlas →
ClinicalTrials.gov19

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07935304Registry update November 13, 2026 · current at observation
  2. NCT07282600Registry update November 4, 2026 · current at observation
  3. NCT07353931Registry update November 4, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span November 19, 2025 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration4,6
  • U.S. Department of Health and Human Services7
Dated updates connected to this profile · 20

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07935304↗

    PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT07282600↗

    PeptideScanner retained ClinicalTrials.gov record NCT07282600 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT07353931↗

    PeptideScanner retained ClinicalTrials.gov record NCT07353931 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07369011↗

    PeptideScanner retained ClinicalTrials.gov record NCT07369011 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07392190↗

    PeptideScanner retained ClinicalTrials.gov record NCT07392190 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT07900633↗

    PeptideScanner retained ClinicalTrials.gov record NCT07900633 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT07215559↗

    PeptideScanner retained ClinicalTrials.gov record NCT07215559 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-09, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT07589608↗

    PeptideScanner retained ClinicalTrials.gov record NCT07589608 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT07808060↗

    PeptideScanner retained ClinicalTrials.gov record NCT07808060 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT07701083↗

    PeptideScanner retained ClinicalTrials.gov record NCT07701083 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT07321886↗

    PeptideScanner retained ClinicalTrials.gov record NCT07321886 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was eloralintide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07738614↗

    PeptideScanner retained ClinicalTrials.gov record NCT07738614 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-20, and PeptideScanner's reviewed identity mapping was eloralintide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT07321886 · retained source version 2026-09-22:853c308f9115135e14872b98fe113b21ed3bfd2bf85ee60f72affd9103c5f058 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT07353931 · retained source version 2026-11-04:be753ffcfe702bced4354977a9b85db8f84552fe7410c39e988f4f276610507c ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    ClinicalTrials.gov record NCT07369011 · retained source version 2026-11-04:968753a1a8c36a1c4cf24c5469b814552e751bf040a09ba642cb216c9db2ac1b ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  4. 4
    Eloralintide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  5. 5
    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025) · PMID 41207310 ↗

    The Lancet · Official source · Source checked November 15, 2026

  6. 6
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026